FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978402006> ?p ?o ?g. }

• W1978402006 endingPage "293" @default.
• W1978402006 startingPage "284" @default.
• W1978402006 abstract "BACKGROUND Prostate cancer is the most commonly diagnosed neoplasm and the second leading cause of male death in this country. Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. However, the molecular mechanisms underlying the disease remain largely unknown. The major difficulty in the clinical management of prostate cancer stems from the reality that reliable and accurate diagnostic/prognostic biomarkers are not available and that effective treatment regimens for hormone-resistant prostate cancers are yet to be developed. METHODS The present review, through extensive literature research, summarizes the most recently accumulated experimental and clinical data on the relationship between apoptosis and prostate cancer. We analyze the possibility of inducing prostate cancer cell apoptosis by: 1) androgen ablation by castration or biochemical antagonists: 2) chemotherapeutic drugs or natural/synthetic chemicals; 3) manipulation of apoptosis-related oncoproteins; and 4) modulation of intracellular signal transducers. RESULTS 1) Prostate cancer, like most other solid tumors, represents a very heterogeneous entity. Most prostate cancers, at the time of clinical diagnosis, present themselves as mixtures of androgen-dependent and androgen-independent cells. 2) Most prostate cancers respond initially to androgen ablation since the population of androgen-dependent cells undergoes rapid apoptosis upon androgen withdrawal. However, androgen ablation rarely cures patients, most of whom will experience recurrence due to takeover of the tumor mass by androgen-independent tumor cells as well as the emergence of apoptosis-resistant clones as a result of further genetic alterations such as bcl-2 amplification. 3) On the other hand, although androgen-independent prostate cancer cells do not undergo apoptosis upon androgen blocking, they do maintain the appropriate molecular machinery of apoptosis. Therefore, certain conventional chemotherapy drugs can eliminate androgen-independent cancer cells by inducing apoptosis. 4) However, most drugs used in chemotherapy induce apoptosis or mediate cytotoxicity only in proliferating cancer cells. Human prostate cancer cells demonstrate very slow growth kinetics. Thus, novel chemical/natural products need be identified to eradicate those nonproliferating cancer cells. In this regard, the angiogenesis inhibitor, linomide, and a plant extract, β-lapachone, demonstrate very promising apoptosis-inducing effects on prostate cancer cells in a proliferation-independent manner. 5) An alternative way to modulate the apoptotic response is by interfering with the expression levels of essential regulatory molecule of apoptosis. Bcl-2 and p53 represent two prime targets for such manipulations. 6) Finally, modulation of signal transduction pathways (e.g., intracellular Ca2+ levels, PKC activity) involved in apoptosis may also induce and/or enhance the apoptotic response of prostate cancer cells. CONCLUSIONS Modulation of apoptotic response represents a novel mechanism-based approach which may help identify novel drugs and/or develop new therapeutic regimens for the treatment of prostate cancers. Prostate 32:284–293, 1997. © 1997 Wiley-Liss, Inc." @default.
• W1978402006 created "2016-06-24" @default.
• W1978402006 creator A5012137553 @default.
• W1978402006 creator A5083990383 @default.
• W1978402006 date "1997-09-01" @default.
• W1978402006 modified "2023-10-18" @default.
• W1978402006 title "Target to apoptosis: A hopeful weapon for prostate cancer" @default.
• W1978402006 cites W1501238827 @default.
• W1978402006 cites W1595972372 @default.
• W1978402006 cites W1611610664 @default.
• W1978402006 cites W1798204859 @default.
• W1978402006 cites W1865272626 @default.
• W1978402006 cites W1964327547 @default.
• W1978402006 cites W1976385326 @default.
• W1978402006 cites W1978810719 @default.
• W1978402006 cites W1980942225 @default.
• W1978402006 cites W1984247829 @default.
• W1978402006 cites W1989780564 @default.
• W1978402006 cites W1989963027 @default.
• W1978402006 cites W1991644963 @default.
• W1978402006 cites W1999012962 @default.
• W1978402006 cites W2002599993 @default.
• W1978402006 cites W2003301112 @default.
• W1978402006 cites W2004605778 @default.
• W1978402006 cites W2005182680 @default.
• W1978402006 cites W2005808983 @default.
• W1978402006 cites W2013464193 @default.
• W1978402006 cites W2014651848 @default.
• W1978402006 cites W2015309835 @default.
• W1978402006 cites W2017352211 @default.
• W1978402006 cites W2021402322 @default.
• W1978402006 cites W2023809975 @default.
• W1978402006 cites W2028999918 @default.
• W1978402006 cites W2031465452 @default.
• W1978402006 cites W2036752555 @default.
• W1978402006 cites W2038421530 @default.
• W1978402006 cites W2049985014 @default.
• W1978402006 cites W2052371698 @default.
• W1978402006 cites W2052744271 @default.
• W1978402006 cites W2057713336 @default.
• W1978402006 cites W2062413760 @default.
• W1978402006 cites W2062620124 @default.
• W1978402006 cites W2065968028 @default.
• W1978402006 cites W2067020779 @default.
• W1978402006 cites W2067847877 @default.
• W1978402006 cites W2073415946 @default.
• W1978402006 cites W2077452186 @default.
• W1978402006 cites W2078001244 @default.
• W1978402006 cites W2078923413 @default.
• W1978402006 cites W2079542852 @default.
• W1978402006 cites W2080889643 @default.
• W1978402006 cites W2081197593 @default.
• W1978402006 cites W2081324739 @default.
• W1978402006 cites W2089579900 @default.
• W1978402006 cites W2090898609 @default.
• W1978402006 cites W2092335156 @default.
• W1978402006 cites W2092368761 @default.
• W1978402006 cites W2092516221 @default.
• W1978402006 cites W2095330944 @default.
• W1978402006 cites W2098470595 @default.
• W1978402006 cites W2098631187 @default.
• W1978402006 cites W2101617519 @default.
• W1978402006 cites W2102821757 @default.
• W1978402006 cites W2109568316 @default.
• W1978402006 cites W2115487618 @default.
• W1978402006 cites W2120715370 @default.
• W1978402006 cites W2136648921 @default.
• W1978402006 cites W2137874814 @default.
• W1978402006 cites W2178615409 @default.
• W1978402006 cites W2206538661 @default.
• W1978402006 cites W2327947202 @default.
• W1978402006 cites W2340073049 @default.
• W1978402006 doi "https://doi.org/10.1002/(sici)1097-0045(19970901)32:4<284::aid-pros9>3.0.co;2-j" @default.
• W1978402006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9288188" @default.
• W1978402006 hasPublicationYear "1997" @default.
• W1978402006 type Work @default.
• W1978402006 sameAs 1978402006 @default.
• W1978402006 citedByCount "185" @default.
• W1978402006 countsByYear W19784020062012 @default.
• W1978402006 countsByYear W19784020062013 @default.
• W1978402006 countsByYear W19784020062014 @default.
• W1978402006 countsByYear W19784020062015 @default.
• W1978402006 countsByYear W19784020062016 @default.
• W1978402006 countsByYear W19784020062017 @default.
• W1978402006 countsByYear W19784020062018 @default.
• W1978402006 countsByYear W19784020062019 @default.
• W1978402006 countsByYear W19784020062020 @default.
• W1978402006 countsByYear W19784020062021 @default.
• W1978402006 countsByYear W19784020062022 @default.
• W1978402006 countsByYear W19784020062023 @default.
• W1978402006 crossrefType "journal-article" @default.
• W1978402006 hasAuthorship W1978402006A5012137553 @default.
• W1978402006 hasAuthorship W1978402006A5083990383 @default.
• W1978402006 hasConcept C121608353 @default.
• W1978402006 hasConcept C126322002 @default.
• W1978402006 hasConcept C143998085 @default.
• W1978402006 hasConcept C2776235491 @default.
• W1978402006 hasConcept C2777911890 @default.

• next